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a b s t r a c t
Hepatitis B virus (HBV) infection is the leading cause of liver diseases. However, the molecular
mechanisms of HBV infection and carcinogenesis have not been fully elucidated. In this study, we
found that cyclin D2 was upregualted in HBV-expressing cells and liver tissues of HBV-transgenic mice.
Gene silencing of cyclin D2 inhibited HBV DNA replicative intermediates, 3.5 kb mRNA, core protein
level, as well as the secretions of HBsAg and HBeAg. On the contrary, overexpression of cyclin D2
promoted HBV replication. Furthermore, cyclin D2 regulated HBV replication by enhancing the activity of
HBV core and Sp1 promoters by targeting transcription factor CREB2. Silencing of CREB2 abolished
enhancement of HBV replication induced by cyclin D2. Together, our study has uncovered a positive role
of cyclin D2 in HBV replication. It is conceivable that therapeutic application of cyclin D2 inhibitor in HBV
infection therapy.
& 2014 Elsevier Inc. All rights reserved.
Introduction
HBV is the leading cause of acute hepatitis, chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (HCC), affecting more than
240 million people worldwide (Ott et al., 2012). It is particularly
common in Asia, Africa, Southern Europe and Latin America (Lin et
al., 2005). However, the molecular mechanism of HBV replication
remain elusive. Currently, there are two major strategies including
immunomodulatory therapy and direct antiviral therapy applied
for HBV treatment. However, longer term treatment of HBV
patients with nucleoside/nucleotide analogs often results in drug
resistance and with interferon brings about notorious side effects
(Jiao et al., 2012; Micco et al., 2013). Therefore, there is an urgent
need to understand HBV replication at the molecular level and to
probe novel molecular targets for HBV therapy.
HBV carries a small (ca. 3.2 kb), relaxed circular (RC), partially
double-stranded DNA genome (Summers and Mason, 1982). Upon
viral entry into hepatocyte, the viral DNA is ﬁrst converted into a
covalently closed circular DNA, the cccDNA. The cccDNA then
serves as the viral transcriptional template for the synthesis of
pg RNA and subgenomic RNAs that translate into the viral surface
protein, core protein, the viral polymerase, and x protein respec-
tively (Neuveut et al., 2010).
Cyclin D2 (CCND2) is a member of the D-type cyclin family,
which is the main integral mediators associating the extracellular
signaling environment with cell-cycle progression (Zhang et al.,
2013). Cyclin D2 forms a complex with and functions as a
regulatory subunit of CDK4 or CDK6 and shortens the G1 phase
(Kato and Sherr, 1993). Cyclin D2 mainly participates in cell cycle
and cancer progression (Song et al., 2008). Wang et al. demon-
strated that hypermethylation intensity of cyclin D2 promoter
was increased in HBV-related HCC (Wang et al., 2012). Addition-
ally, other cell-cycle regulators p53 and p21 protein has been
reported to be associated with HBV-related HCC (Choi et al.,
2001). These ﬁndings suggested the association between cell-
cycle regulators and HBV-related HCC. So far, studies focused on
the direct relation between cyclin D2 and HBV infection are very
limited.
In this study, we analyzed the differentially expressed genes in
HBV replication cell model HepG2.2.15 (Bird and Sells, 1987) and
HepG2 cells using gene microarray analysis. The results showed
that cyclin D2 was signiﬁcantly upregulated in the presence of the
replicating HBV genome. Knockdown of cyclin D2 inhibited HBV
replication, whereas overexpression of cyclin D2 promoted HBV
replication. Furthermore, we discovered that cyclin D2 could
regulate activities of HBV core and Sp1 promoters possibly by
targeting transcription factor CREB2. Our ﬁndings implicated a role
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of cyclin D2 in HBV replication and have identiﬁed a host factor in
HBV life cycle.
Results
Upregulation of cyclin D2 in HBV-expressing cells
The gene expression proﬁle was compared in HepG2.2.15
which is a HBV stably transfected cell line constitutively producing
HBV and HepG2 cells by using gene expression array. Array-based
transcriptional mapping indicated that transcription of the HBV
genome altered several genes expression involved in cell cycle
regulation. Among them, the expression of cyclin D2 (CCND2) was
upregulated more than 14 folds in HepG2.2.15 compared with
HepG2 (Zhang et al., 2010). To determine whether cyclin D2 was
specially upregulated by HBV, the mRNA level of cyclin D2 was
ﬁrst examined in HepG2.2.15, HepG2 cells transiently transfected
with HBV expressing plasmid pCH9/3091 (containing 1. 1-unit
length HBV genome driven by CMV promoter) or pGEM-HBV1.3
(containing 1.3-unit length HBV genome driven by endogenous
viral promoter) and control cells. The real-time PCR conﬁrmed that
cyclin D2 was upregulated nearly 16 folds in HepG2.2.15 and
nearly 2 folds in HepG2 cells transfected with HBV expression
plasmid compared with HepG2 cells (Fig. 1A). In addition, several
other cyclin members including cyclin A2, cyclin B1, cyclin B2,
cyclin D1, cyclin C and cyclin E1 were also examined in
HepG2.2.15, HepG2, HepG2 cells transfected with pGEM-HBV1.3
or control vector. The results found that HepG2.2.15 cells showed
higher level of cyclin C and cyclin B1, however, no differentially
expressed cyclins investigated were found in HepG2 cells trans-
fected with pGEM-HBV1.3 (Supplementary Fig. 1A,B). Consistently,
western blotting analysis revealed that HBV replication indeed
upregulated the protein level of cyclin D2 (Fig. 1B). To substantiate
the association between HBV and cyclin D2, the mRNA and protein
level of cyclin D2 were compared in liver tissues of HBV-transgenic
mice and control mice. All the HBV-transgenic mice showed
elevated mRNA and protein level of cyclin D2 in liver tissue
(Fig. 1C,D). Taken together, these data revealed that transcription
of HBV genome upregulated the expression of cyclin D2, suggest-
ing cyclin D2 might play a role in the HBV replication process.
Gene silencing of cyclin D2 inhibited HBV replication
To investigate the possible regulatory effect of cyclin D2 on HBV
replication, HepG2.2.15 was transfected with shRNA targeting
cyclin D2 (shcyclin D2-1 or shcyclin D2-2) or scramble control
shRNA (shCont). Western blotting analysis showed that cyclin D2
was markedly downregulated in HepG2.2.15 cells after transfected
with the two cyclin D2 shRNAs (Fig. 2A). Gene silencing of cyclin
D2 resulted in a 50% decrease in HBV DNA replicative intermedi-
ates in HepG2.2.15 cells as measured by real time PCR (Fig. 2B).
Southern blot also conﬁrmed that signiﬁcant downregulation of
HBV DNA replicative intermediates in cyclin D2-silencing cells
(Fig. 2C). Moreover, real-time PCR revealed that cyclin D2-
silencing cells showed more than 50% reduction of 3.5 kb mRNA
compared with control cells (Fig. 2D). The expression of HBV core
protein was also signiﬁcantly inhibited in HepG2.2.15 cells expres-
sing cyclin D2 shRNAs compared with shCont (Fig. 2E). Knock-
down of cyclin D2 also inhibited the secretion of both HBsAg and
HBeAg (Fig. 2F). On the other hand, the effect of cyclin D2 silencing
on HBV replication was further veriﬁed in Huh-7 cells transiently
transfected with pGEM-HBV1.3. Consistently, silencing of cyclin D2
inhibited HBV DNA replicative intermediates as evidenced by real-
time PCR (Fig. 3A) and Southern blot (Fig. 3B). Cyclin D2 suppres-
sion also inhibited HBV 3.5 Kb mRNA (Fig. 3C) as well as secretion
of both HBsAg and HBeAg (Fig. 3D). Taken together, these data
suggest that knockdown of cyclin D2 may exert the suppressive
effect on HBV replication.
Cyclin D2 enhanced HBV replication
To further elucidate the role of cyclin D2 in HBV replication,
plasmid expressing cyclin D2 or pcDNA3.1 was transfected into
HepG2.2.15 cells respectively. The transfection efﬁciency was ﬁrst
conﬁrmed by using western blotting analysis (Fig. 4A). Real-time
PCR showed that overexpression of cyclin D2 increased the copies
of viral DNA replication by nearly 1.6-fold (Fig. 4B). Southern blot
conﬁrmed that upregulation of HBV DNA replicative intermediates
induced by cyclin D2 overexpression (Fig. 4C). Importantly,
HepG.2.2.15 cells overexpressing cyclin D2 showed 2-fold higher
expression of 3.5 kb mRNA (Fig. 4D). Furthermore, overexpression
of cyclin D2 also increased the expression of HBV core protein
(Fig. 4E) as well as HBsAg and HBeAg secreted in supernatant
(Fig. 4F). These results demonstrated that cyclin D2 enhanced HBV
replication and expression of viral proteins.
Cyclin D2 regulated activities of HBV promoters by targeting
transcription factor CREB2
To uncover how cyclin D2 affected HBV replication, we sought
to identify whether cyclin D2 plays a role in the activity of the HBV
core, X, Sp1 and Sp2 promoters. Luciferase reporter assays showed
that overexpression of cyclin D2 enhanced the activity of core and
Sp1 promoter, but did not affect Xp and Sp2 activities (Fig. 5A). In
contrast, cyclin D2 knockdown inhibited the activity of core and
Sp1 promoters (Fig. 5B). These results suggested that promotive
action of cyclin D2 on HBV replication was possibly due to
activation of HBV core and Sp1 promoters. To further examined
the mechanism of inhibition of cyclin D2 on HBV promoters, a
panel of transcription factors including PPAR-alpha,CREB1, CREB2,
AP-1, COUP-TF1, HNF4, NFκB, p53, p56 and TR2, were screened by
real-time PCR. The result found that cyclin D2 overexpression
increased CREB2 mRNA level (Fig. 6A). Consistently, western
blotting analysis conﬁrmed that overexpression of cyclin D2
promoted CREB2 protein level while cyclin D2 knockdown inhib-
ited CREB2 expression (Fig. 6B). Importantly, the enhancement of
HBV replicative intermediates and 3.5 Kb mRNA induced by cyclin
D2 was partially abolished when CREB2 was suppressed (Fig. 6C,
D). Taken together, these results suggested that cyclin D2 is a
positive regulator of CREB2 and it may upregulate activity of HBV
promoters via CREB2.
Discussion
Host immune system is to clear exogenous pathogens through
immune response and cytokines, while pathogens are to devise
ways to escape host attack and immune surveillance, such as
down-regulating host genes. Zhang et al. demonstrated that host
factor HS3ST3B1 effectively inhibited HBV replication and viral
protein expression (Zhang et al., 2010). Cyclin D2 is known to be
involved in immune responses. Cyclin D2 is ﬁrst induced in T and B
lymphocytes and controls the proliferation of lymphocytes by
regulating the cell cycle (Morito et al., 2011). These reminded us
that cyclin D2 may play an important role in the immune system
between host cells and virus. Recently, a study reported that the
expression of cyclin D2 was reduced in HIV patient CD4þ cells
(Sieg et al., 2001). Another study found that the mRNA level of
cyclin D2 decreased in the HRSV-infected primary airway epithe-
lial cells (Wu et al., 2011). TaeJoon Park et al. found that cyclin
D2 polymorphisms associated with clearance of HBV infection
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(Park et al., 2010). This ﬁnding suggested that cyclin D2 may be
associated with life cycle of HBV replication. In this study, we
found cyclin D2 was closely related to the HBV replication. Gene
microarray analysis found the markedly upregulation of cyclin D2
in cell model of HBV infection. This prompted our investigation
into the role of cyclin D2 in HBV replication. Gain-of-function
and lose-of-function studies found that cyclin D2 could regulate
HBV DNA replicate intermediates, 3.5 kb mRNA, core protein and
HBsAg and HBeAg secretion.
The molecular mechanism of cyclin D2-meidated regulation of
HBV replication was further investigated. The apparent regulation
of HBV replication by cyclin D2 was correlated with regulation of
HBV core and Sp1 promoter activities. HBV transcription is under
the control of four promoter including Core, Sp1, Sp2 and X
promoter. Core promoter is responsible for the transcription of
3.5 kb mRNA. Xp controls the transcription of the mRNA of the X
protein, a promiscuous viral regulator (Murakami, 2001). Sp1
launches transcription of the mRNA encoding the large surface
protein, which is essential for virion formation and infectivity
(Seeger and Mason, 2000). Sp2 guides the synthesis of the preS2/S
transcript encoding the middle and small surface proteins. Con-
sistent with its regulation of core promoter, cyclin D2 regulated
the expression level of core protein and 3.5 kb mRNA transcribed
from core promoter. Similarly, cyclin D2 regulated the HBsAg
Fig. 1. Expression of cyclin D2 in HBV-expressing cells and liver tissue from HBV-transgenic mice. (A) The mRNA level of cyclin D2 in HepG2.2.15, HepG2 and HepG2 cells
transiently transfected with plasmid pCH9/3091 or pGEM-HBV1.3. β-actin mRNA was used as an internal control. npo0.01. (B) Western blotting analysis of cyclin D2 protein
level in HepG2.2.15, HepG2 and HepG2 cells transiently transfected with plasmid pCH9/3091 or pGEM-HBV1.3. β-actin was used as a loading control. (C,D) The mRNA and
protein level of cyclin D2 in liver tissues of HBV-transgenic mice (C57BL/6J) and control mice was analyzed by western blot analysis. β-actin was used as a loading control.
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expression associated with Sp1 promoter. These two promoters of
HBV may act as molecular switches, determining the gene activity.
The “switches” further inﬂuence the transcription and translation
of HBV gene, resulting in the overall effect on HBV replication.
However, results are still preliminary, and detailed molecular
mechanism of regulation of HBV replication mediated by cyclin
D2 needs to be determined.
Cyclin D2 is well-known to be involved in the regulation of cell
cycle progression. Importantly, it is also an important signal
molecule in several signaling pathways. Trans-activator protein
(Tax) of Human T-cell leukemia virus type I (HTLV-I) induced
activation of cyclin D2 through NFκB (Iwanaga et al., 2008). Cyclin
D2 is an important downstream target of the PI3-K/PKB signaling
pathway (Fernandez et al., 2004). Myc-cyclin D2-p27 signaling
pathway plays an important role in cell cycle progression of
quiescent cells (Bouchard et al., 1999). MiR-206 inhibits prolifera-
tion of breast cancer cell through up-regulation of cyclin D2
(Zhou et al., 2013). Efﬁcient transcription HBV genes require a
number of host transcription factors. Various transcription factors
are reported to bind to HBV core promoter region including
speciﬁcity protein 1(Sp1), Peroxisome proliferator-activated recep-
tor alpha (PPAR-alpha), hepatocyte nuclear factor 4 (HNF4),
Fig. 2. Gene silencing of cyclin D2 inhibited HBV replication in HepG2.2.15 cells. (A) The knockdown efﬁciency of shcyclin D2-1 and shcyclin D2-2 in HepG2.2.15 cells was
analyzed by using western blotting analysis. HepG2.2.15 cells was transfected with plasmid expressing scramble (shCont) or cyclin D2-targeting shRNAs (shcyclin D2-1 or
shcyclin D2-2). Cells were harvested 5 days after transfection. (B,C) Effects of cyclin D2 knockdown on HBV DNA replicative intermediates in HepG2.2.15 cells. HBV replicative
intermediates were extracted from nucleocapsid 5 days after transfection. B, Real-time PCR of HBV DNA. Results are expressed as number of HBV DNA copies per cell.
*po0.001. C, Southern blot analysis. M, ladder; RC, intracellular HBV relax circle; DS, double strand DNA; SS, single strand DNA. (D) 3.5 kb mRNA level was analyzed by using
selective primers and β-actin primers (equal loading of each RNA samples). npo0.01. (E) Cyclin D2 knockdown down-regulated HBV core protein expression. (F) The
expression of HBsAg and HBeAg in supernatant were detected by using ELISA assay.The O.D. values were expressed as percentage relative to the shCont. npo0.01.
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C-AMP-response element binding protein (CREB), nuclear factor-
kappa B (NFκB), et al. HBV Sp1 promoter contains binding sites of
HNF1, HNF3а and HNF3β, Octamer transcription factor 1(Oct1),
et al. Based on the ﬁnding that cyclin D2 could regulate the core
and Sp1 promoter activities, we hypothesized that cyclin D2 alone
or combined with other signaling molecules may be involved in
the regulation of certain HBV-related transcription factors. To test
this hypothesis, we screened various transcription factors related
to HBV transcription, and found that CREB2 was possibly involved
in the regulation of HBV promoter by cyclin D2. CREB transcription
factors are key regulators of homeostatic functions in the liver
(Servillo et al., 2002), and CRE binding is increased in hepatic
inﬂammation (Servillo et al., 2002). In terms of HBV, Tacke et al.
found that CREB inducer protein kinase A (PKA) resulted in HBV-S
mRNA induction and enhanced small envelope protein expression
(Tacke et al., 2005). Kim et al. showed that both replication and
gene expression of HBV require a functional CREB and HBV-CRE
(Kim et al., 2008). In this study, we found that cyclin D2 could
regulate CREB2 mRNA and protein levels. Gene silencing of CREB2
abolished partially enhancement of HBV replication induced by
cyclin D2. Although the mechanism by which cyclin D2 promoted
HBV replication remains to be further investigated, this study
suggests that activation of CREB2 is probably involved.
Brieﬂy, we identiﬁed a novel host gene, cyclin D2, facilitates
efﬁciently HBV replication by enhancing its core and Sp1 promo-
ters' activities. Our study provided valuable information to
understand the interaction between host factors and HBV. Further
study should be devoted to investigate the detailed mechanism of
cyclin D2-mediated HBV regulation and explore if cyclin D2 could
be an anti-HBV target.
Materials and methods
Plasmids and antibodies
HBV replication plasmid pCH9/3091 was a gift from Prof. Lin
Lan (The Third Military Medical University, China). pCH9/3091
plasmid containing HBV1.1 was driven by CMV promoter. pGEM-
HBV1.3 was a gift from Dr. Protzer (University of Heidelberg,
Heidelberg, Germany). pcDNA3.1-cyclin D2 was purchased from
addgene (addgene, USA), plasmid plentilox3.7 was from Invitrogen
Life Technologies (Invitrogen, USA), cyclin D2 antibody was from
Cell Signaling Technology (CST, USA), CREB2 antibody was from
Santa Cruz Technology (SC-200) and HBV core antibody was from
Dako (Dako, Denmark).
Cell culture and transfection
HepG2 was purchased from ATCC (American Type Culture
Collection, USA) and was maintained in Dulbecco's modiﬁed
Eagle's medium (DMEM) with 10% fetal bovine serum (gibco,
Fig. 3. Cyclin D2 knockdown inhibited HBV replication in Huh-7 cells transiently expressing HBV. (A,B) Effect of cyclin D2 suppression on HBV DNA replicative intermediates
in Huh-7 cells transfected with pGEM-HBV1.3. Huh-7 cells transfected with cyclin D2 shRNAs 5 days after transfection with pGEM-HBV1.3. The HBV replicative intermediates
were then analyzed by real-time PCR (A) and southern blot (B). npo0.01. (C) Cylin D2 inhibited HBV 3.5 Kb mRNA by real-time PCR. (D) HBsAg and HBeAg secreted in the
supernatant were analyzed by using ELISA assay. The O.D. values were expressed as percentage relative to the shCont. npo0.01.
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USA). HepG2.2.15 was purchased from Shanghai Second Military
Medical University and was maintained in MEM (gibco, USA)
containing 10% fetal bovine serum and 500 μg/ml G418. The two
cell lines were authenticated by short tandem repeat proﬁling
analysis and maintained in a humidiﬁed incubator at 37 1C with 5%
CO2. Transfection was carried out using Lipofectamine 2000TM
(Invitrogen, USA).
Knockdown of cyclin D2 with short hairpin RNA (shRNA) interfering
shRNA targeting cyclin D2 was generated by inserting short
hairpin RNA (shRNA) sequence into lentivirus plasmid vector
plentilox3.7. Oligonucleotide sequence of shcyclin D2-1: positive-
sense strand, 50-TCGTCGATGATCGCAACTGGAATTCAAGAGATTC-
CAGTTGCGATCATCGACGTTTTTTC-30; Oligonucleotide sequence of
Fig. 4. Overexpression of cyclin D2 enhanced HBV replication. (A)Western blotting analysis was used to conﬁrm the transfection efﬁciency of cyclin D2 in HepG2.2.15 cells.
HepG2.2.15 cells were transfected with plasmid expressing cyclin D2 or corresponding empty vector (pcDNA3.1), respectively. Cells were harvested 5 days after plasmid
transfection. (B,C) The level of HBV DNA replicative intermediates was analyzed in cells ectopically expressing cyclin D2 by using real-time PCR (B) and Southern blot analysis
(C). (D) HBV 3.5 kb mRNA level was analyzed by real-time PCR using 3.5 kb mRNA selective primers. β-actin mRNA was used as an internal control. npo0.01. (E) HBV core
protein expression was analyzed by western blot analysis. (F) The expression of HBsAg and HBeAg in the culture supernatant were quantiﬁed by using ELISA assay. npo0.01.
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shcyclin D2-2: positive-sense strand, 50-TGAAGGACATCCAACCCTA-
CATTTCAAGAGAATGTAGGGTTGGATGTCCTTCTTTTTTC-3'; Sequence
of control shRNA (shCont) is 50-GCAACAAGATGAAGAGCACCAA-30.
Western blotting analysis
Total protein was extracted using RIPA buffer containing
protease inhibitors (Roche, Germany). Concentration of proteins
was determined by the protein assay Reagent (Bio-Rad, USA).
Protein lysates with 30 μg of protein were separated by SDS-PAGE,
transferred to a nitrocellulose membrane (GE Healthcare, UK), and
immunoblotted with antibodies as indicated (Anti-cyclin D2
1:800; Anti-core protein 1:1000; Anti-β-actin 1:3000). Blots were
developed with ECL Western blotting reagents (Millipore, USA). β-
actin (Santa Cruz, USA) was used as loading reference for data
analysis.
Real-time PCR
Absolute quantiﬁcation of HBV replicative intermediates were
carried out using Fast Start Universal SYBR Green Master (Roche,
Germany). Relative quantiﬁcation of cyclin D2 and the 3.5Kb mRNA
were performed using the SYBR Green Master and the reactions were
carried out using an IQTM 5 Multicolor Real-Time PCR Detection
system (Bio-Rad, USA). The cDNA was synthesized from 1 μg of total
RNA using iScript™ cDNA Synthesis Kit according to manufacturer's
protocol (Bio-Rad, USA). β-actin mRNA was used as endogenous
control. The level of expression in different treatments was quantiﬁed
using an optimized comparative Ct (ΔΔCt) value method. Cyclin D2
speciﬁc primers: forward primer, 50-CACCGACTTTAAGTTTGCCA-30,
reverse primer, 50-TTGGTGATCTTAGCCAGCAG-30. 3.5 kb mRNA speciﬁc
primers: forward primer, 50-GCCTTAGAGTCTCCTGAGCA-30, reversepri-
mer, 50-GAGGGAGTTCTTCTTCTAGG-30. The primers for quantifying β-
actin are 50-CTCTTCCAGCCTTCCTTCCT-30 and 50-AGCACTGTGTTGGCG-
TACAG-30. HBV speciﬁc primers: forward primer, 50-CCTAGTAGTCAGT-
TATGTCAAC-30,reverse primer, 50-TCTATAAGCTGGAGGAGTGCGA-30. All
the samples were cycled once 95 1C for 2 min, then 34 cycles of 94 1C
for 20 s, 60 1C for 20 s, and 72 1C for 20 s. Values represent the
mean7SD of three independent experiments.
Enzyme linked immunosorbent assay (ELISA)
Five days after transfection, the expression of HBsAg and
HBeAg in cell culture medium were detected using two different
commercial ELISA kits (KHB, Shanghai, China). All assays were
performed according to the manufacturer's instructions.
Luciferase reporter assay
pGL3-Cp, pGL3-Xp, pGL3-Sp1, pGL3-Sp2 were constructed
through replace SV40 promoter with 4 of HBV inner promoters
into vector pGL3-basic. These four different plasmids were trans-
fected with cyclin D2 or pcDNA3.1 vector control, respectively.
Three days after transfection; cells were harvested and assayed by
the Dual Luciferase Report Assay System (Promega, USA) after
transfection three days, according to the manufacturer's instruc-
tions. pRL-TK was cotransfected with reporter plasmid to normal-
ize transfection efﬁciency. Luciferase activity was determined by a
GloMax microplate luminometer (Promega, USA).
Detection of HBV DNA replicative intermediates by Southern blot
HBV DNA replicative intermediates in HBV core particles
isolated from transfected HepG2.2.15 cells were analyzed using
Southern blot. The normalized viral DNA replicative intermediates
were electrophoresed onto a 0.9% agarose gel. Then DNA was
transferred onto a positive nylon membrane (Roche, Germany)
in 20 SSC. After ﬁxing at 120 1C for 30 min, the membrane
was prehybridized for 1 h at 42 1C in DIG Easy hyb Granules,
and then hybridized with full-length HBV DNA probes labeled
Fig. 5. Cyclin D2 regulated activities of HBV promoters. (A) Different luciferase
reporter vectors were co-transfected with pcDNA3.1-cyclin D2 into HepG2 cells.
The plasmid RL-TK was co-transfected to normalize the transfection efﬁciency.
Luciferase activity was measured 72 h after transfection. For each group, three
independent experiments were conducted. npo0.001. (B) Different luciferase
reporter vectors were co-transfected with shcyclin D2-1 or shcyclin D2-2
into HepG2 cells. The plasmid RL-TK was co-transfected to normalize the
transfection efﬁciency. Luciferase activity was measured 72 h after transfection.
npo0.001.
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with DIG by DIG High prime DNA labeling and detection starter
kit (Roche, Germany) under the same condition of prehybridiza-
tion overnight. The signal was detected by exposing on an
X-ray ﬁlm.
Statistical analysis
Values were expressed as means7SD. Differences were
evaluated by two-tailed Student's t tests or one-way ANOVA.
Fig. 6. Cyclin D2 regulated transcription factor CREB2 expression. (A) A panel of HBV-related transcription factors were screened in HepG2.2.15 cells overexpressing cyclin D2
by using real-time PCR. npo0.01. (B) The effect of cyclin D2 on CREB2 expression was analyzed by western blotting analysis. Overexpression of cyclin D2 promoted CREB2
protein level (Left panel) while cyclin D knockdown inhibited CREB2 expression (Right panel). (C,D) The effect of CREB2 silencing on HBV DNA replicative intermediates in
HepG2.2.15 cells overexpressing cyclin D2. HepG2.2.15 co-transfected with indicated plasmids and siRNA were harvested for HBV replicative intermediates analysis by real-
time PCR (C) and Southern blot (D). (E) HBV 3.5 kb mRNA level in HepG2.2.15 cells transfected with indicated plasmids and siRNA was analyzed by real-time PCR. npo0.01.
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All statistical analysis was carried out by the statistical program,
SPSS version 16.0 (SPSS, Inc, Chicago, IL). P value o0.05 was
considered statistically signiﬁcant.
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